vs
Natural Grocers by Vitamin Cottage, Inc.（NGVC）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Natural Grocers by Vitamin Cottage, Inc.の直近四半期売上が大きい（$335.6M vs $177.4M、Pacira BioSciences, Inc.の約1.9倍）。Natural Grocers by Vitamin Cottage, Inc.の純利益率が高く（3.4% vs 1.6%、差は1.7%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs 1.6%）。過去8四半期でNatural Grocers by Vitamin Cottage, Inc.の売上複合成長率が高い（4.4% vs -0.2%）
Natural Grocers by Vitamin Cottage, Inc.は米国発の専門小売チェーンで、認定オーガニック食品、栄養補助食品、天然由来のパーソナルケア商品、環境配慮型の家庭用品を取り扱っています。健康志向の消費者を主な顧客層とし、米国複数州に店舗を展開し、人工添加物を含む商品を排除する厳格な品質基準を遵守しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
NGVC vs PCRX — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $335.6M | $177.4M |
| 純利益 | $11.3M | $2.9M |
| 粗利率 | 29.5% | — |
| 営業利益率 | 4.4% | 3.9% |
| 純利益率 | 3.4% | 1.6% |
| 売上前年比 | 1.6% | 5.0% |
| 純利益前年比 | 14.0% | — |
| EPS（希薄化後） | $0.49 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $177.4M | ||
| Q4 25 | $335.6M | $196.9M | ||
| Q3 25 | $336.1M | $179.5M | ||
| Q2 25 | $328.7M | $181.1M | ||
| Q1 25 | $335.8M | $168.9M | ||
| Q4 24 | $330.2M | $187.3M | ||
| Q3 24 | $322.7M | $168.6M | ||
| Q2 24 | $309.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $11.8M | $5.4M | ||
| Q2 25 | $11.6M | $-4.8M | ||
| Q1 25 | $13.1M | $4.8M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.0M | $-143.5M | ||
| Q2 24 | $9.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 29.5% | 79.5% | ||
| Q3 25 | 29.5% | 80.9% | ||
| Q2 25 | 29.9% | 77.4% | ||
| Q1 25 | 30.3% | 79.7% | ||
| Q4 24 | 29.9% | 78.7% | ||
| Q3 24 | 29.6% | 76.9% | ||
| Q2 24 | 29.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.4% | 1.2% | ||
| Q3 25 | 4.6% | 3.5% | ||
| Q2 25 | 4.7% | 4.7% | ||
| Q1 25 | 5.2% | 1.2% | ||
| Q4 24 | 4.0% | 13.2% | ||
| Q3 24 | 3.7% | -82.8% | ||
| Q2 24 | 4.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.5% | 3.0% | ||
| Q2 25 | 3.5% | -2.7% | ||
| Q1 25 | 3.9% | 2.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 2.8% | -85.1% | ||
| Q2 24 | 3.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.49 | $0.05 | ||
| Q3 25 | $0.51 | $0.12 | ||
| Q2 25 | $0.50 | $-0.11 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.43 | $0.38 | ||
| Q3 24 | $0.38 | $-3.11 | ||
| Q2 24 | $0.40 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $23.2M | $144.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $220.0M | $653.9M |
| 総資産 | $668.6M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $144.3M | ||
| Q4 25 | $23.2M | $238.4M | ||
| Q3 25 | $17.1M | $246.3M | ||
| Q2 25 | $13.2M | $445.9M | ||
| Q1 25 | $21.2M | $493.6M | ||
| Q4 24 | $6.3M | $484.6M | ||
| Q3 24 | $8.9M | $453.8M | ||
| Q2 24 | $13.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $220.0M | $693.1M | ||
| Q3 25 | $212.4M | $727.2M | ||
| Q2 25 | $202.5M | $757.8M | ||
| Q1 25 | $193.0M | $798.5M | ||
| Q4 24 | $181.9M | $778.3M | ||
| Q3 24 | $174.3M | $749.6M | ||
| Q2 24 | $167.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $668.6M | $1.3B | ||
| Q3 25 | $670.5M | $1.3B | ||
| Q2 25 | $659.0M | $1.5B | ||
| Q1 25 | $664.6M | $1.6B | ||
| Q4 24 | $648.9M | $1.6B | ||
| Q3 24 | $655.5M | $1.5B | ||
| Q2 24 | $654.4M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $21.1M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $11.6M | — |
| FCFマージンFCF / 売上 | 3.4% | — |
| 設備投資強度設備投資 / 売上 | 2.9% | — |
| キャッシュ転換率営業CF / 純利益 | 1.86× | — |
| 直近12ヶ月FCF直近4四半期 | $42.6M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $21.1M | $43.7M | ||
| Q3 25 | $15.6M | $60.8M | ||
| Q2 25 | $2.9M | $12.0M | ||
| Q1 25 | $34.1M | $35.5M | ||
| Q4 24 | $2.7M | $33.1M | ||
| Q3 24 | $24.5M | $53.9M | ||
| Q2 24 | $12.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.6M | $43.5M | ||
| Q3 25 | $7.5M | $57.0M | ||
| Q2 25 | $-4.2M | $9.3M | ||
| Q1 25 | $27.6M | $26.9M | ||
| Q4 24 | $-6.9M | $31.0M | ||
| Q3 24 | $18.0M | $49.8M | ||
| Q2 24 | $3.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 22.1% | ||
| Q3 25 | 2.2% | 31.7% | ||
| Q2 25 | -1.3% | 5.1% | ||
| Q1 25 | 8.2% | 15.9% | ||
| Q4 24 | -2.1% | 16.6% | ||
| Q3 24 | 5.6% | 29.6% | ||
| Q2 24 | 1.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 0.1% | ||
| Q3 25 | 2.4% | 2.2% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | 2.9% | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.86× | — | ||
| Q3 25 | 1.32× | 11.20× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 2.60× | 7.37× | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 2.72× | — | ||
| Q2 24 | 1.35× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
